Literature DB >> 24852515

Conditioning techniques and ischemic reperfusion injury in relation to on-pump cardiac surgery.

Fredrik Eric Olof Holmberg1, Konstantin Alex Ottas, Charlotte Andreasen, Mario J Perko, Christian H Møller, Thomas Engstrøm, Daniel A Steinbrüchel.   

Abstract

OBJECTIVES: The objective was to investigate the potential protective effects of two conditioning methods, on myocardial ischemic and reperfusion injury in relation to cardiac surgery.
DESIGN: Totally 68 patients were randomly assigned to either a control group (n = 23), a remote ischemic preconditioning (RIPC) group (n = 23) or a glucagon-like peptide-1 (GLP-1) analogue group (n = 22). The RIPC protocol consisted of three cycles of upper limb ischemia. The GLP-1 analogue protocol consisted of intravenous infusion with exenatide. The primary endpoint was postoperative cardiac enzyme release. The other secondary endpoints were metabolic parameters related to myocardial ischemia, measured using microdialysis technique, as well as other operative- and postoperative data.
RESULTS: Postoperative cardiac enzyme release indicated a possible beneficial effect of the interventions, but the difference did not reach statistical significance. RIPC showed a trend toward lower levels (p = 0.07). We managed to establish a functional myocardial microdialysis model, but we were unable to demonstrate clear protective effects.
CONCLUSIONS: We were in this prospective randomized proof-of-concept trial, unable to show distinct protective effects of the studied conditioning methods. However, this trial can hopefully contribute to generate a productive discussion concerning limitations and future use of cardiac conditioning as well as microdialysis technique.

Entities:  

Keywords:  glucagon-like peptide 1 analogue; microdialysis; remote ischemic preconditioning; reperfusion injury

Mesh:

Substances:

Year:  2014        PMID: 24852515     DOI: 10.3109/14017431.2014.923930

Source DB:  PubMed          Journal:  Scand Cardiovasc J        ISSN: 1401-7431            Impact factor:   1.589


  7 in total

Review 1.  Remote ischemic conditioning.

Authors:  Gerd Heusch; Hans Erik Bøtker; Karin Przyklenk; Andrew Redington; Derek Yellon
Journal:  J Am Coll Cardiol       Date:  2015-01-20       Impact factor: 24.094

Review 2.  Ischaemic preconditioning for the reduction of renal ischaemia reperfusion injury.

Authors:  Theo P Menting; Kimberley E Wever; Denise Md Ozdemir-van Brunschot; Daan Ja Van der Vliet; Maroeska M Rovers; Michiel C Warle
Journal:  Cochrane Database Syst Rev       Date:  2017-03-04

Review 3.  Heart-type fatty acid binding protein (H-FABP) as a biomarker for acute myocardial injury and long-term post-ischemic prognosis.

Authors:  Xiao-Dong Ye; Yi He; Sheng Wang; Gordon T Wong; Michael G Irwin; Zhengyuan Xia
Journal:  Acta Pharmacol Sin       Date:  2018-05-17       Impact factor: 6.150

Review 4.  Noncoding RNAs and myocardial fibrosis.

Authors:  Thomas Thum
Journal:  Nat Rev Cardiol       Date:  2014-09-09       Impact factor: 32.419

5.  Perioperative plasma mitochondrial DNA dynamics and correlation with inflammation during infantile cardiopulmonary bypass.

Authors:  Fei Xu; Rui-Qi Liu; Rong Cao; Lang-Tao Guo; Ning Zhang; Ke Huang; Yu Cui; Wei-Na Li; Lei Li; Zheng-Hua Huang
Journal:  Indian Heart J       Date:  2017-03-28

6.  Systematic review of incretin therapy during peri-operative and intensive care.

Authors:  Abraham H Hulst; Mark P Plummer; Markus W Hollmann; J Hans DeVries; Benedikt Preckel; Adam M Deane; Jeroen Hermanides
Journal:  Crit Care       Date:  2018-11-14       Impact factor: 9.097

7.  Liraglutide for perioperative management of hyperglycaemia in cardiac surgery patients: a multicentre randomized superiority trial.

Authors:  Abraham H Hulst; Maarten J Visscher; Marc B Godfried; Bram Thiel; Bastiaan M Gerritse; Thierry V Scohy; R Arthur Bouwman; Mark G A Willemsen; Markus W Hollmann; Benedikt Preckel; J Hans DeVries; Jeroen Hermanides
Journal:  Diabetes Obes Metab       Date:  2019-12-17       Impact factor: 6.577

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.